Doxorubicin

Last updated

Doxorubicin
Doxorubicin.svg
Doxorubicin 3D ball.png
Clinical data
Pronunciation /ˌdɒksəˈruːbɪsɪn/
Trade names Adriamycin, Caelyx, [1] Myocet, [2] others
Biosimilars Zolsketil pegylated liposomal, [3] Celdoxome pegylated liposomal [4]
AHFS/Drugs.com Monograph
MedlinePlus a682221
License data
Pregnancy
category
  • AU:D
Routes of
administration 		intravenous, intravesical
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability 5% (by mouth)
Protein binding 75% [8]
Metabolism Liver
Elimination half-life Triphasic; 12 minutes, 3.3 hours, 30 hours. Mean: 1–3 hours [8] [9]
Excretion Urine (5–12%), faeces (40–50%) [8]
Identifiers
  • (7S,9S)-7-[(2R,4S,5S,6S)-4-Amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard 100.041.344 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C27H29NO11
Molar mass 543.525 g·mol−1
3D model (JSmol)
  • C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](Cc3c2c(c4c(c3O)C(=O)c5cccc(c5C4=O)OC)O)(C(=O)CO)O)N)O
  • InChI=1S/C27H29NO11/c1-10-22(31)13(28)6-17(38-10)39-15-8-27 (36,16(30)9–29)7-12-19(15)26(35)21–20(24(12)33)23 (32)11-4-3-5-14(37–2)18(11)25(21)34/h3-5,10,13,15, 17,22,29,31,33,35-36H,6–9,28H2,1-2H3/t10-,13-,15-,17-,22+,27-/m0/s1 X mark.svgN
  • Key:AOJJSUZBOXZQNB-TZSSRYMLSA-N Yes check.svgY
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Doxorubicin, sold under the brand name Adriamycin among others, is a chemotherapy medication used to treat cancer. [10] This includes breast cancer, bladder cancer, Kaposi's sarcoma, lymphoma, and acute lymphocytic leukemia. [10] It is often used together with other chemotherapy agents. [10] Doxorubicin is given by injection into a vein. [10]

Contents

Common side effects include hair loss, bone marrow suppression, vomiting, rash, and inflammation of the mouth. [10] Other serious side effects may include allergic reactions such as anaphylaxis, heart damage, tissue damage at the site of injection, radiation recall, and treatment-related leukemia. [10] People often experience red discoloration of the urine for a few days. [10] Doxorubicin is in the anthracycline and antitumor antibiotic family of medications. [10] It works in part by interfering with the function of DNA. [11]

Doxorubicin was approved for medical use in the United States in 1974. [10] It is on the World Health Organization's List of Essential Medicines. [12] [13] Versions that are pegylated and in liposomes are also available; however, they are more expensive. [13] Doxorubicin was originally made from the bacterium Streptomyces peucetius . [14]

Medical uses

In the EU doxorubicin pegylated liposomal (as Caelyx) is indicated to treat breast cancer, ovarian cancer, and AIDS-related Kaposi's sarcoma. It is indicated to treat multiple myeloma in combination with bortezomib. [1] Doxorubicin hydrochloride (as Myocet liposomal) is indicated to treat breast cancer in combination with cyclophosphamide. [2]

Doxorubicin is commonly used to treat some leukemias and lymphomas, as well as cancers of the bladder, breast, stomach, lung, ovaries, thyroid, soft tissue sarcoma as well as aggressive fibromatosis (desmoid tumor), multiple myeloma, and others. [9] [15] [16] Commonly used doxorubicin-containing regimens are AC (Adriamycin, cyclophosphamide), TAC (taxotere, AC), ABVD (Adriamycin, bleomycin, vinblastine, dacarbazine), BEACOPP, CHOP (cyclophosphamide, hydroxydaunorubicin, vincristine, prednisone) and FAC (5-fluorouracil, adriamycin, cyclophosphamide). [9] Its activity is inhibited by certain antioxidant plant extracts, for example Tragia volubilis aqueous extract. [17]

Doxil (see below) is used primarily for the treatment of ovarian cancer where the disease has progressed or recurred after platinum-based chemotherapy, or for the treatment of AIDS-related Kaposi's sarcoma. [18]

Side effects

Cardiotoxicity

The most dangerous side effect of doxorubicin is dilated cardiomyopathy, leading to congestive heart failure. The rate of cardiomyopathy is dependent on its cumulative dose, with an incidence about 4% when the dose of doxorubicin is 500–550 mg/m2, 18% when the dose is 551–600 mg/m2 and 36% when the dose exceeds 600 mg/m2. [19] There are several ways in which doxorubicin is believed to cause cardiomyopathy, including oxidative stress due to iron accumulation, downregulation of genes for contractile proteins, and p53-mediated apoptosis. [19] [20]

Doxorubicin-induced cardiomyopathy typically results in dilated cardiomyopathy, with all four cardiac chambers being enlarged. [21] This results in both systolic and diastolic dysfunction. [21] Eventually, heart failure can result, which carries a 50% mortality rate. [21] There is no effective treatment against established cardiomyopathy caused by the drug as of 2010. [21] The drug dexrazoxane, which is an iron chelator may be used to decrease the risk of doxorubicin's cardiotoxicity in certain cases. [22]


Other

Another common and potentially fatal complication of doxorubicin is typhlitis, an acute life-threatening inflammation of the bowel. [23] Additionally, some people may develop palmar plantar erythrodysesthesia (PPE), characterized by skin eruptions on the palms of the hand or soles of the feet, swelling, pain, and erythema. [18] Due to these side effects and its red color, doxorubicin has earned the nickname "red devil" [24] [25] or "red death." [26]

Chemotherapy can cause reactivation of hepatitis B, and doxorubicin-containing regimens are no exception. [27] [28]

Doxorubicin and several chemotherapeutic drugs (including cyclophosphamide) can cause a loss of skin pigmentation. [29]

Liposomal formulations

There is a pegylated (polyethylene glycol coated) liposome-encapsulated form of doxorubicin, developed to treat Kaposi's sarcoma. The polyethylene glycol coating results in preferential concentration of doxorubicin in the skin. However, this also results in a side effect called palmar plantar erythrodysesthesia (PPE), more commonly known as hand-foot syndrome.

Following administration of this form of doxorubicin, small amounts of the drug can leak from capillaries in the palms of the hands and soles of the feet. The result of this leakage is redness, tenderness, and peeling of the skin that can be uncomfortable and even painful. In clinical testing at 50 mg/m2 dosing every four weeks, half of people developed hand-foot syndrome. The rate of this side effect limits the dose of this formulation that can be given as compared with plain doxorubicin in the same treatment regimen, thereby limiting potential substitution. Substitution would be desirable because liposome-encapsulated doxorubicin is less cardiotoxic than unencapsulated doxorubicin. This liposome-encapsulated form is also approved by the FDA for treatment of ovarian cancer and multiple myeloma. [30] [31]

A non-pegylated liposomal doxorubicin, called Myocet, is approved in the European Union and in Canada for the treatment of metastatic breast cancer in combination with cyclophosphamide, [2] but it has not been approved by the FDA for use in the United States. Unlike Doxil, the Myocet liposome does not have a polyethylene glycol coating, and therefore does not result in the same rate of PPE. The minimization of this side effect may allow for one-for-one (1:1) substitution with doxorubicin in the same treatment regimen, thereby improving safety with no loss of efficacy. Like Doxil, the liposomal encapsulation of the doxorubicin limits the cardiotoxicity. In theory, by limiting the cardiotoxicity of doxorubicin through liposomal encapsulation, it can be used safely in concurrent combination with other cardiotoxic chemotherapy drugs, such as trastuzumab. There is an FDA black box warning that trastuzumab cannot be used in concurrent combination with doxorubicin, only in sequential combination. Though concurrent combination of trastuzumab and doxorubicin in clinical studies found superior tumor response, the combination resulted in unacceptable cardiotoxicity, including risk of cardiac failure manifesting as congestive heart failure (CHF). Published phase II study results have shown that Myocet, trastuzumab, and paclitaxel can safely be used concurrently without the cardiac risk, as measured by reduction in LVEF function, while still achieving superior tumor response. This finding is the basis for the ongoing phase III trial for FDA approval. [30]

Biosynthesis

Doxorubicin (DXR) is a 14-hydroxylated version of daunorubicin, the immediate precursor of DXR in its biosynthetic pathway.

Daunorubicin is more abundantly found as a natural product because it is produced by a number of different wild type strains of Streptomyces . In contrast, only one known non-wild type species, Streptomyces peucetius subspecies cesius ATCC 27952, was initially found to be capable of producing the more widely used doxorubicin. [32] This strain was created by Arcamone et al. in 1969 by mutating a strain producing daunorubicin, but not DXR, at least in detectable quantities. [33] Subsequently, Hutchinson's group showed that under special environmental conditions, or by the introduction of genetic modifications, other strains of Streptomyces can produce doxorubicin. [34] His group also cloned many of the genes required for DXR production, although not all of them have been fully characterized. In 1996, Strohl's group discovered, isolated and characterized dox A, the gene encoding the enzyme that converts daunorubicin into DXR. [35]

By 1999, they produced recombinant dox A, a cytochrome P450 oxidase, and found that it catalyzes multiple steps in DXR biosynthesis, including steps leading to daunorubicin. [36] This was significant because it became clear that all daunorubicin-producing strains have the necessary genes to produce DXR, the much more therapeutically important of the two. Hutchinson's group went on to develop methods to improve the yield of DXR, from the fermentation process used in its commercial production, not only by introducing dox A encoding plasmids, but also by introducing mutations to deactivate enzymes that shunt DXR precursors to less useful products, for example baumycin-like glycosides. [32] Some triple mutants, that also over-expressed dox A, were able to double the yield of DXR. This is of more than academic interest, because at that time DXR cost about $1.37 million per kg and current production in 1999 was 225 kg per annum. [37]

More efficient production techniques have brought the price down to $1.1 million per kg for the nonliposomal formulation. Although DXR can be produced semi-synthetically from daunorubicin, the process involves electrophilic bromination and multiple steps, and the yield is poor. [38] Since daunorubicin is produced by fermentation, it would be ideal if the bacteria could complete DXR synthesis more effectively.

Mechanism of action

Diagram of two doxorubicin molecules intercalating DNA, from PDB: 1D12 . Doxorubicin-DNA complex 1D12.png
Diagram of two doxorubicin molecules intercalating DNA, from PDB: 1D12 ​.

Doxorubicin interacts with DNA by intercalation and inhibition of macromolecular biosynthesis. [11] [40] [41] This inhibits the progression of topoisomerase II, an enzyme which relaxes supercoils in DNA for transcription. [42] Doxorubicin stabilizes the topoisomerase II complex after it has broken the DNA chain for replication, preventing the DNA double helix from being released and thereby stopping the process of replication. [11] It may also increase quinone type free radical production, hence contributing to its cytotoxicity. [15]

The planar aromatic chromophore portion of the molecule intercalates between two base pairs of the DNA, while the six-membered daunosamine sugar sits in the minor groove and interacts with flanking base pairs immediately adjacent to the intercalation site, as evidenced by several crystal structures. [39] [43]

By intercalation, doxorubicin can also induce histone eviction from transcriptionally active chromatin. [44] [45] As a result, the DNA damage response, epigenome and transcriptome are deregulated in doxorubicin-exposed cells. [44]

History

Bacteria producing doxorubicin were originally discovered in soil near Castel del Monte, Apulia. Andria - Castel del Monte - 202209012324.jpg
Bacteria producing doxorubicin were originally discovered in soil near Castel del Monte, Apulia.

In the 1950s, an Italian research company, Farmitalia Research Laboratories, began an organized effort to find anticancer compounds from soil-based microbes. A soil sample was isolated from the area surrounding the Castel del Monte, a 13th-century castle. A new strain of Streptomyces peucetius , which produced a red pigment, was isolated, and an antibiotic from this bacterium was effective against tumors in mice. Since a group of French researchers discovered the same compound at about the same time, the two teams named the compound daunorubicin, combining the name Dauni , a pre-Roman tribe that occupied the area of Italy where the compound was isolated, with the French word for ruby, rubis, describing the color. [46] [47] [48] Clinical trials began in the 1960s, and the drug was successful in treating acute leukemia and lymphoma. However, by 1967, it was recognized that daunorubicin could lead to fatal cardiac toxicity. [49]

Researchers at Farmitalia soon discovered that changes in biological activity could be made by minor changes in the structure of the compound. A strain of Streptomyces was mutated using N-nitroso-N-methyl urethane, and this new strain produced a different, red-colored antibiotic. They named this new compound Adriamycin, after the Adriatic Sea, and the name was later changed to doxorubicin to conform to the established naming convention. [33] Doxorubicin showed better activity than daunorubicin against mouse tumors, and especially solid tumors. It also showed a higher therapeutic index, yet the cardiotoxicity remained. [50]

Doxorubicin and daunorubicin together can be thought of as prototype compounds for the anthracyclines. Subsequent research has led to many other anthracycline antibiotics, or analogs, and there are now over 2,000 known analogs of doxorubicin. By 1991, 553 of them had been evaluated in the screening program at the National Cancer Institute (NCI). [46] In 2016 GPX-150 was granted orphan drug designation by US FDA. [51]

Society and culture

On 24 March 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Zolsketil pegylated liposomal, intended for the treatment of metastatic breast cancer, advanced ovarian cancer, progressive multiple myeloma and AIDS-related Kaposi's sarcoma. [52] The applicant for this medicinal product is Accord Healthcare S.L.U. [52] Zolsketil pegylated liposomal is a hybrid medicine of Adriamycin. [52] It contains the same active substance as Adriamycin, but is available in a pegylated liposomal formulation. [52] Zolsketil pegylated liposomal was approved for medical use in the European Union in May 2022. [3] [53]

On 21 July 2022, the CHMP adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Celdoxome pegylated liposomal, intended for the treatment of metastatic breast cancer, advanced ovarian cancer, progressive multiple myeloma and AIDS-related Kaposi's sarcoma. [54] The applicant for this medicinal product is YES Pharmaceutical Development Services GmbH. [54] Celdoxome pegylated liposomal is a hybrid medicine of Adriamycin which has been authorized in the EU since 24 October 1979. [54] Celdoxome pegylated liposomal contains the same active substance as Adriamycin, but is available in a pegylated liposomal formulation. [54] Celdoxome pegylated liposomal was approved for medical use in the European Union in September 2022. [4]

Names

It is also known as hydroxydaunorubicin and hydroxydaunomycin. [55]

It is sold under a number of different brand names, including Adriamycin PFS, Adriamycin RDF, or Rubex. [9]

Formulations

Doxorubicin is photosensitive, and containers are often covered by an aluminum bag and/or brown wax paper to prevent light from affecting it. [9] Doxorubicin is also available in liposome-encapsulated forms as Doxil (pegylated form), Myocet (nonpegylated form), and Caelyx, [1] which are also given by intravenous injection. [9]

The FDA approved the first generic version of Doxil, made by Sun, in February 2013. [56]

Research

Combination therapy experiments with sirolimus (rapamycin) and doxorubicin have shown promise in treating Akt-positive lymphomas in mice. [57]

Further, the release of photo-activated adriamycin with the aid of nanoporous optical antenna resulted in significant anti-cancer effect in MCF-7 breast cancer cells. [58] In 2006, animal research coupling a murine monoclonal antibody with doxorubicin created an immunoconjugate that was able to eliminate HIV-1 infection in mice. [59] [60]

Antimalarial activity

There is some evidence for antimalarial activity for doxorubicin and similar compounds. In 2009, a compound similar in structure to doxorubicin was found to inhibit plasmepsin II, an enzyme unique to the malarial parasite Plasmodium falciparum . [61] The pharmaceutical company GlaxoSmithKline (GSK) later identified doxorubicin in a set of compounds that inhibit parasite growth. [62]

Fluorescence

Doxorubicin is also known to be fluorescent. This has often been used to characterize doxorubicin concentrations, and has opened the possibility of using the molecule as a theranostic agent. However, there are significant limitations, as doxorubicin's fluorescence spectrum is known to depend on a variety of factors, including the pH of the environment, solvent dielectric constant and others. Doxorubicin fluorescence is quenched by binding to DNA, and shielded by micelle encapsulation. It is also known to self-quench at high concentrations. In contrast, histone binding amplifies fluorescence. [63] [64]

Related Research Articles

<span class="mw-page-title-main">Antimetabolite</span> Chemical that inhibits the use of a metabolite

An antimetabolite is a chemical that inhibits the use of a metabolite, which is another chemical that is part of normal metabolism. Such substances are often similar in structure to the metabolite that they interfere with, such as the antifolates that interfere with the use of folic acid; thus, competitive inhibition can occur, and the presence of antimetabolites can have toxic effects on cells, such as halting cell growth and cell division, so these compounds are used in chemotherapy for cancer.

<span class="mw-page-title-main">Daunorubicin</span> Chemotherapy medication

Daunorubicin, also known as daunomycin, is a chemotherapy medication used to treat cancer. Specifically it is used for acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), and Kaposi's sarcoma. It is administered by injection into a vein. A liposomal formulation known as liposomal daunorubicin also exists.

<span class="mw-page-title-main">Anthracycline</span> Class of antibiotics

Anthracyclines are a class of drugs used in cancer chemotherapy that are extracted from Streptomyces peucetius bacterium. These compounds are used to treat many cancers, including leukemias, lymphomas, breast, stomach, uterine, ovarian, bladder cancer, and lung cancers. The first anthracycline discovered was daunorubicin, which is produced naturally by Streptomyces peucetius, a species of Actinomycetota. Clinically the most important anthracyclines are doxorubicin, daunorubicin, epirubicin and idarubicin.

<span class="mw-page-title-main">Epirubicin</span> Chemical compound

Epirubicin is an anthracycline drug used for chemotherapy. It can be used in combination with other medications to treat breast cancer in patients who have had surgery to remove the tumor. It is marketed by Pfizer under the trade name Ellence in the US and Pharmorubicin or Epirubicin Ebewe elsewhere.

<span class="mw-page-title-main">CHOP (chemotherapy)</span> Treatment for non-Hodgkin lymphoma

CHOP is the acronym for a chemotherapy regimen used in the treatment of non-Hodgkin lymphoma. CHOP consists of:

Cardiotoxicity is the occurrence of heart dysfunction as electric or muscle damage, resulting in heart toxicity. This can cause heart failure, arrhythmia, myocarditis, and cardiomyopathy in patients. Some effects are reversible, while in others, permanent damage requiring further treatment may arise. The heart becomes weaker and is not as efficient in pumping blood. Cardiotoxicity may be caused by chemotherapy treatment and/or radiotherapy; complications from anorexia nervosa; adverse effects of heavy metals intake; the long-term abuse of or ingestion at high doses of certain strong stimulants such as cocaine; or an incorrectly administered drug such as bupivacaine.

<span class="mw-page-title-main">Primary effusion lymphoma</span> Medical condition

Primary effusion lymphoma (PEL) is classified as a diffuse large B cell lymphoma. It is a rare malignancy of plasmablastic cells that occurs in individuals that are infected with the Kaposi's sarcoma-associated herpesvirus. Plasmablasts are immature plasma cells, i.e. lymphocytes of the B-cell type that have differentiated into plasmablasts but because of their malignant nature do not differentiate into mature plasma cells but rather proliferate excessively and thereby cause life-threatening disease. In PEL, the proliferating plasmablastoid cells commonly accumulate within body cavities to produce effusions, primarily in the pleural, pericardial, or peritoneal cavities, without forming a contiguous tumor mass. In rare cases of these cavitary forms of PEL, the effusions develop in joints, the epidural space surrounding the brain and spinal cord, and underneath the capsule which forms around breast implants. Less frequently, individuals present with extracavitary primary effusion lymphomas, i.e., solid tumor masses not accompanied by effusions. The extracavitary tumors may develop in lymph nodes, bone, bone marrow, the gastrointestinal tract, skin, spleen, liver, lungs, central nervous system, testes, paranasal sinuses, muscle, and, rarely, inside the vasculature and sinuses of lymph nodes. As their disease progresses, however, individuals with the classical effusion-form of PEL may develop extracavitary tumors and individuals with extracavitary PEL may develop cavitary effusions.

<span class="mw-page-title-main">Trabectedin</span> Chemical compound

Trabectedin, sold under the brand name Yondelis, is an antitumor chemotherapy medication for the treatment of advanced soft-tissue sarcoma and ovarian cancer.

<span class="mw-page-title-main">Breast cancer chemotherapy</span> Medical intervention

Breast cancer chemotherapy refers to the use of cytotoxic drugs (chemotherapy) in the treatment of breast cancer.

<span class="mw-page-title-main">Biosynthesis of doxorubicin</span>

Doxorubicin (DXR) is a 14-hydroxylated version of daunorubicin, the immediate precursor of DXR in its biosynthetic pathway. Daunorubicin is more abundantly found as a natural product because it is produced by a number of different wild type strains of Streptomyces. In contrast, only one known non-wild type species, Streptomyces peucetius subspecies caesius ATCC 27952, was initially found to be capable of producing the more widely used doxorubicin. This strain was created by Arcamone et al. in 1969 by mutating a strain producing daunorubicin, but not DXR, at least in detectable quantities. Subsequently, Hutchinson's group showed that under special environmental conditions, or by the introduction of genetic modifications, other strains of streptomyces can produce doxorubicin. His group has also cloned many of the genes required for DXR production, although not all of them have been fully characterized. In 1996, Strohl's group discovered, isolated and characterized dox A, the gene encoding the enzyme that converts daunorubicin into DXR. By 1999, they produced recombinant Dox A, a Cytochrome P450 oxidase, and found that it catalyzes multiple steps in DXR biosynthesis, including steps leading to daunorubicin. This was significant because it became clear that all daunorubicin producing strains have the necessary genes to produce DXR, the much more therapeutically important of the two. Hutchinson's group went on to develop methods to improve the yield of DXR, from the fermentation process used in its commercial production, not only by introducing Dox A encoding plasmids, but also by introducing mutations to deactivate enzymes that shunt DXR precursors to less useful products, for example baumycin-like glycosides. Some triple mutants, that also over-expressed Dox A, were able to double the yield of DXR. This is of more than academic interest because at that time DXR cost about $1.37 million per kg and current production in 1999 was 225 kg per annum. More efficient production techniques have brought the price down to $1.1 million per kg for the non-liposomal formulation. Although DXR can be produced semi-synthetically from daunorubicin, the process involves electrophilic bromination and multiple steps and the yield is poor. Since daunorubicin is produced by fermentation, it would be ideal if the bacteria could complete DXR synthesis more effectively.

<span class="mw-page-title-main">Pixantrone</span> Chemical compound

Pixantrone is an experimental antineoplastic (anti-cancer) drug, an analogue of mitoxantrone with fewer toxic effects on cardiac tissue. It acts as a topoisomerase II poison and intercalating agent. The code name BBR 2778 refers to pixantrone dimaleate, the actual substance commonly used in clinical trials.

<span class="mw-page-title-main">Kaposi's sarcoma</span> Cancer of the skin, integumentary lymph nodes, or other organs

Kaposi's sarcoma (KS) is a type of cancer that can form masses on the skin, in lymph nodes, in the mouth, or in other organs. The skin lesions are usually painless, purple and may be flat or raised. Lesions can occur singly, multiply in a limited area, or may be widespread. Depending on the sub-type of disease and level of immune suppression, KS may worsen either gradually or quickly. Except for Classical KS where there is generally no immune suppression, KS is caused by a combination of immune suppression and infection by Human herpesvirus 8.

<span class="mw-page-title-main">OSI-7904</span> Chemical compound

OSI-7904 is a noncompetitive liposomal thymidylate synthase inhibitor. OSI-7904 is a benzoquinazoline folate analog with antineoplastic activity. As a thymidylate synthase inhibitor, OSI-7904 noncompetitively binds to thymidylate synthase, resulting in inhibition of thymine nucleotide synthesis and DNA replication.

<span class="mw-page-title-main">Follicular dendritic cell sarcoma</span> Dendritic cell sarcoma cancer that effects the follicular dendritic cells

Follicular dendritic cell sarcoma (FDCS) is an extremely rare neoplasm. While the existence of FDC tumors was predicted by Lennert in 1978, the tumor wasn't fully recognized as its own cancer until 1986 after characterization by Monda et al. It accounts for only 0.4% of soft tissue sarcomas, but has significant recurrent and metastatic potential and is considered an intermediate grade malignancy. The major hurdle in treating FDCS has been misdiagnosis. It is a newly characterized cancer, and because of its similarities in presentation and markers to lymphoma, both Hodgkin and Non-Hodgkin subtypes, diagnosis of FDCS can be difficult. With recent advancements in cancer biology better diagnostic assays and chemotherapeutic agents have been made to more accurately diagnose and treat FDCS.

Microbubbles are bubbles smaller than one hundredth of a millimetre in diameter, but larger than one micrometre. They have widespread application in industry, medicine, life science, and food technology. The composition of the bubble shell and filling material determine important design features such as buoyancy, crush strength, thermal conductivity, and acoustic properties.

Streptomyces peucetius is a bacterium species in the genus Streptomyces.

This is a historical timeline of the development and progress of cancer treatments, which includes time of discovery, progress, and approval of the treatments.

Bradley J. Monk is an American gynecologic oncologist, academician and researcher. He is a professor on the Clinical Scholar Track in the Department of Obstetrics and Gynecology at the University of Arizona College of Medicine in Phoenix, Arizona, as well as at the Creighton University School of Medicine in Omaha, Nebraska. He also serves as Director of the Division of Gynecologic Oncology at the St. Joseph's Hospital and Medical Center in Phoenix.

pH-responsive tumor-targeted drug delivery is a specialized form of targeted drug delivery that utilizes nanoparticles to deliver therapeutic drugs directly to cancerous tumor tissue while minimizing its interaction with healthy tissue. Scientists have used drug delivery as a way to modify the pharmacokinetics and targeted action of a drug by combining it with various excipients, drug carriers, and medical devices. These drug delivery systems have been created to react to the pH environment of diseased or cancerous tissues, triggering structural and chemical changes within the drug delivery system. This form of targeted drug delivery is to localize drug delivery, prolongs the drug's effect, and protect the drug from being broken down or eliminated by the body before it reaches the tumor.

Immunoliposome therapy is a targeted drug delivery method that involves the use of liposomes coupled with monoclonal antibodies to deliver therapeutic agents to specific sites or tissues in the body. The antibody modified liposomes target tissue through cell-specific antibodies with the release of drugs contained within the assimilated liposomes. Immunoliposome aims to improve drug stability, personalize treatments, and increased drug efficacy. This form of therapy has been used to target specific cells, protecting the encapsulated drugs from degradation in order to enhance their stability, to facilitate sustained drug release and hence to advance current traditional cancer treatment.

References

  1. 1 2 3 4 "Caelyx pegylated liposomal EPAR". European Medicines Agency (EPAR). 17 September 2018. Archived from the original on 21 June 2022. Retrieved 20 June 2022.
  2. 1 2 3 4 "Myocet liposomal EPAR". European Medicines Agency. 17 September 2018. Archived from the original on 25 February 2022. Retrieved 20 June 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  3. 1 2 3 "Zolsketil pegylated liposomal EPAR". European Medicines Agency (EMA). 24 January 2022. Archived from the original on 21 June 2022. Retrieved 20 June 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  4. 1 2 3 "Celdoxome pegylated liposomal EPAR". European Medicines Agency (EMA). 20 June 2022. Retrieved 31 January 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  5. ↑ "Caelyx product information". Health Canada . 25 April 2012. Archived from the original on 21 June 2022. Retrieved 20 June 2022.
  6. ↑ "Myocet product information". Health Canada . 25 April 2012. Retrieved 20 June 2022.
  7. ↑ "Taro-doxorubicin liposomal product information". Health Canada . 25 April 2012. Archived from the original on 14 May 2021. Retrieved 20 June 2022.
  8. 1 2 3 "(doxorubicin) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Archived from the original on 16 April 2014. Retrieved 15 April 2014.
  9. 1 2 3 4 5 6 Brayfield A, ed. (19 December 2013). "Doxorubicin". Martindale: The Complete Drug Reference. Pharmaceutical Press. Archived from the original on 28 August 2021. Retrieved 15 April 2014.
  10. 1 2 3 4 5 6 7 8 9 "Doxorubicin Hydrochloride". The American Society of Health-System Pharmacists. Archived from the original on 11 October 2016. Retrieved 12 January 2017.
  11. 1 2 3 Tacar O, Sriamornsak P, Dass CR (February 2013). "Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems". The Journal of Pharmacy and Pharmacology. 65 (2): 157–170. doi: 10.1111/j.2042-7158.2012.01567.x . PMID   23278683. S2CID   34737360.
  12. ↑ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl: 10665/325771 . WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  13. 1 2 British national formulary : BNF 69 (69 ed.). British Medical Association. 2015. p. 583. ISBN   9780857111562.
  14. ↑ Ravina E (2011). The Evolution of Drug Discovery: From Traditional Medicines to Modern Drugs. John Wiley & Sons. p. 291. ISBN   9783527326693. Archived from the original on 18 September 2017.
  15. 1 2 Rossi S, ed. (2013). Australian Medicines Handbook (2013 ed.). Adelaide: The Australian Medicines Handbook Unit Trust. ISBN   978-0-9805790-9-3.
  16. ↑ Alman B, Attia S, Baumgarten C, Benson C, Blay JY, Bonvalot S, et al. (Desmoid Tumor Working Group) (March 2020). "The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients". European Journal of Cancer. 127: 96–107. doi: 10.1016/j.ejca.2019.11.013 . hdl: 2318/1793788 . PMID   32004793. S2CID   210998595.
  17. ↑ Bailon-Moscoso N, Coronel-Hidalgo J, Duarte-Casar R, Guamán-Ortiz LM, Figueroa JG, Romero-Benavides JC (November 2023). "Exploring the Antioxidant Potential of Tragia volubilis L.: Mitigating Chemotherapeutic Effects of Doxorubicin on Tumor Cells". Antioxidants. 12 (11): 2003. doi: 10.3390/antiox12112003 . ISSN   2076-3921. PMC   10669231 . PMID   38001856.
  18. 1 2 " "DOXIL Product Information" (PDF). Archived from the original (PDF) on 21 September 2007. Retrieved 19 April 2007.
  19. 1 2 Chatterjee K, Zhang J, Honbo N, Karliner JS (January 2010). "Doxorubicin cardiomyopathy". Cardiology. 115 (2): 155–162. doi:10.1159/000265166. PMC   2848530 . PMID   20016174.
  20. ↑ Ichikawa Y, Ghanefar M, Bayeva M, Wu R, Khechaduri A, Naga Prasad SV, et al. (February 2014). "Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation". The Journal of Clinical Investigation. 124 (2): 617–630. doi:10.1172/JCI72931. PMC   3904631 . PMID   24382354.
  21. 1 2 3 4 Chatterjee K, Zhang J, Honbo N, Karliner JS (2010). "Doxorubicin cardiomyopathy". Cardiology. 115 (2): 155–162. doi:10.1159/000265166. PMC   2848530 . PMID   20016174.
  22. ↑ "Dexrazoxane Hydrochloride Monograph for Professionals - Drugs.com". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 1 August 2018. Retrieved 1 August 2018.
  23. ↑ Kaczmarek A, Brinkman BM, Heyndrickx L, Vandenabeele P, Krysko DV (March 2012). "Severity of doxorubicin-induced small intestinal mucositis is regulated by the TLR-2 and TLR-9 pathways". The Journal of Pathology. 226 (4): 598–608. doi:10.1002/path.3009. PMID   21960132. S2CID   206325412.[ permanent dead link ]
  24. ↑ "Outpatient Oncology Drug Series: Doxorubicin is the Infamous Red Devil". Archived from the original on 21 April 2018. Retrieved 21 April 2018.
  25. ↑ Bloch R, Bloch A. "25 Most Asked Questions". Fighting Cancer. R. A. Bloch Cancer Foundation. Archived from the original on 26 June 2007. Retrieved 28 June 2007.
  26. ↑ Groopman JE (2007). How Doctors Think. Boston: Houghton Mifflin. p.  49. ISBN   978-0-618-61003-7.
  27. ↑ Yeo W, Lam KC, Zee B, Chan PS, Mo FK, Ho WM, et al. (November 2004). "Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy". Annals of Oncology. 15 (11): 1661–1666. doi: 10.1093/annonc/mdh430 . PMID   15520068.
  28. ↑ Dillon R, Hirschfield GM, Allison ME, Rege KP (July 2008). "Fatal reactivation of hepatitis B after chemotherapy for lymphoma". BMJ. 337: a423. doi:10.1136/bmj.39490.680498.BE. PMID   18595895. S2CID   11661945.
  29. ↑ "Image Challenge | NEJM". Archived from the original on 16 March 2013. Retrieved 1 September 2011.
  30. 1 2 "Liposomal doxorubicin (Caelyx, Myocet)". Macmillan Cancer Support. 1 April 2009. Archived from the original on 29 November 2009. Retrieved 27 November 2009.
  31. ↑ "Doxorubicin liposomal". Chemocare. Cleveland Clinic. Archived from the original on 2 January 2010. Retrieved 27 November 2009.
  32. 1 2 Lomovskaya N, Otten SL, Doi-Katayama Y, Fonstein L, Liu XC, Takatsu T, et al. (January 1999). "Doxorubicin overproduction in Streptomyces peucetius: cloning and characterization of the dnrU ketoreductase and dnrV genes and the doxA cytochrome P-450 hydroxylase gene". Journal of Bacteriology. 181 (1): 305–318. doi:10.1128/JB.181.1.305-318.1999. PMC   103563 . PMID   9864344.
  33. 1 2 Arcamone F, Cassinelli G, Fantini G, Grein A, Orezzi P, Pol C, et al. (November 1969). "Adriamycin, 14-hydroxydaunomycin, a new antitumor antibiotic from S. peucetius var. caesius". Biotechnology and Bioengineering. 11 (6): 1101–1110. doi:10.1002/bit.260110607. PMID   5365804. S2CID   21897153.
  34. ↑ Grimm A, Madduri K, Ali A, Hutchinson CR (December 1994). "Characterization of the Streptomyces peucetius ATCC 29050 genes encoding doxorubicin polyketide synthase". Gene. 151 (1–2): 1–10. doi: 10.1016/0378-1119(94)90625-4 . PMID   7828855.
  35. ↑ Dickens ML, Strohl WR (June 1996). "Isolation and characterization of a gene from Streptomyces sp. strain C5 that confers the ability to convert daunomycin to doxorubicin on Streptomyces lividans TK24". Journal of Bacteriology. 178 (11): 3389–3395. doi:10.1128/jb.178.11.3389-3395.1996. PMC   178102 . PMID   8655530.
  36. ↑ Walczak RJ, Dickens ML, Priestley ND, Strohl WR (January 1999). "Purification, properties, and characterization of recombinant Streptomyces sp. strain C5 DoxA, a cytochrome P-450 catalyzing multiple steps in doxorubicin biosynthesis". Journal of Bacteriology. 181 (1): 298–304. doi:10.1128/JB.181.1.298-304.1999. PMC   103562 . PMID   9864343.
  37. ↑ Hutchinson CR, Colombo AL (July 1999). "Genetic engineering of doxorubicin production in Streptomyces peucetius: a review". Journal of Industrial Microbiology & Biotechnology. 23 (1): 647–652. doi:10.1038/sj.jim.2900673. PMID   10455495. S2CID   27337697.
  38. ↑ Lown JW (November 1993). "Anthracycline and anthraquinone anticancer agents: current status and recent developments". Pharmacology & Therapeutics. 60 (2): 185–214. doi:10.1016/0163-7258(93)90006-Y. PMID   8022857.
  39. 1 2 Frederick CA, Williams LD, Ughetto G, van der Marel GA, van Boom JH, Rich A, et al. (March 1990). "Structural comparison of anticancer drug-DNA complexes: adriamycin and daunomycin". Biochemistry. 29 (10): 2538–2549. doi:10.1021/bi00462a016. PMID   2334681. Crystal structure is available for download as a PDB Archived 14 January 2008 at the Wayback Machine file.
  40. ↑ Fornari FA, Randolph JK, Yalowich JC, Ritke MK, Gewirtz DA (April 1994). "Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells". Molecular Pharmacology. 45 (4): 649–656. PMID   8183243.
  41. ↑ Momparler RL, Karon M, Siegel SE, Avila F (August 1976). "Effect of adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cells". Cancer Research. 36 (8): 2891–2895. PMID   1277199. Archived from the original on 5 February 2009.
  42. ↑ Pommier Y, Leo E, Zhang H, Marchand C (May 2010). "DNA topoisomerases and their poisoning by anticancer and antibacterial drugs". Chemistry & Biology. 17 (5): 421–433. doi: 10.1016/j.chembiol.2010.04.012 . PMC   7316379 . PMID   20534341.
  43. ↑ Pigram WJ, Fuller W, Hamilton LD (January 1972). "Stereochemistry of intercalation: interaction of daunomycin with DNA". Nature. 235 (53): 17–19. doi:10.1038/newbio235017a0. PMID   4502404.
  44. 1 2 Pang B, Qiao X, Janssen L, Velds A, Groothuis T, Kerkhoven R, et al. (2013). "Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin". Nature Communications. 4 (5): 1908. Bibcode:2013NatCo...4.1908P. doi:10.1038/ncomms2921. PMC   3674280 . PMID   23715267.
  45. ↑ Pang B, de Jong J, Qiao X, Wessels LF, Neefjes J (July 2015). "Chemical profiling of the genome with anti-cancer drugs defines target specificities". Nature Chemical Biology. 11 (7): 472–480. doi:10.1038/nchembio.1811. PMID   25961671.
  46. 1 2 Weiss RB (December 1992). "The anthracyclines: will we ever find a better doxorubicin?". Seminars in Oncology. 19 (6): 670–686. PMID   1462166.
  47. ↑ Baruffa G (1966). "Clinical trials in Plasmodium falciparum malaria with a long-acting sulphonamide". Transactions of the Royal Society of Tropical Medicine and Hygiene. 60 (2): 222–224. doi:10.1016/0035-9203(66)90030-7. PMID   5332105.
  48. ↑ Per prior citation, the first publication: Camerino B, Palamidessi G (1960). "Derivati della parazina II. Sulfonamdopir". Gazz Chim Ital (in Italian). 90: 1802–1815.
  49. ↑ Tan C, Tasaka H, Yu KP, Murphy ML, Karnofsky DA (March 1967). "Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia". Cancer. 20 (3): 333–353. doi: 10.1002/1097-0142(1967)20:3<333::AID-CNCR2820200302>3.0.CO;2-K . PMID   4290058. S2CID   19272219.
  50. ↑ Di Marco A, Gaetani M, Scarpinato B (February 1969). "Adriamycin (NSC-123,127): a new antibiotic with antitumor activity". Cancer Chemotherapy Reports. 53 (1): 33–37. PMID   5772652.
  51. ↑ Investigational Sarcoma Drug GPX-150 Gets Orphan Drug Designation. 2016 Archived 24 January 2016 at the Wayback Machine
  52. 1 2 3 4 "Zolsketil pegylated liposomal: Pending EC decision". European Medicines Agency (EMA). 24 March 2022. Archived from the original on 29 March 2022. Retrieved 29 March 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  53. ↑ "Zolsketil Product information". Union Register of medicinal products. Retrieved 3 March 2023.
  54. 1 2 3 4 "Celdoxome pegylated liposomal: Pending EC decision". European Medicines Agency (EMA). 22 July 2022. Archived from the original on 28 July 2022. Retrieved 30 July 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  55. ↑ "Doxorubicin: MedlinePlus Drug Information". medlineplus.gov. Archived from the original on 13 July 2020. Retrieved 12 July 2020.
  56. ↑ "FDA approval of generic version of cancer drug Doxil is expected to help resolve shortage" (Press release). U.S. Food and Drug Administration (FDA). 4 February 2013. Archived from the original on 28 February 2014. Retrieved 22 February 2014.
  57. ↑ Wendel HG, De Stanchina E, Fridman JS, Malina A, Ray S, Kogan S, et al. (March 2004). "Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy". Nature. 428 (6980): 332–337. Bibcode:2004Natur.428..332W. doi:10.1038/nature02369. PMID   15029198. S2CID   4426215.
  58. ↑ Saha T, Mondal J, Khiste S, Lusic H, Hu ZW, Jayabalan R, et al. (September 2021). "Nanotherapeutic approaches to overcome distinct drug resistance barriers in models of breast cancer". Nanophotonics. 10 (12): 3063–3073. Bibcode:2021Nanop..10..142S. doi: 10.1515/nanoph-2021-0142 . PMC   8478290 . PMID   34589378.
  59. ↑ Johansson S, Goldenberg DM, Griffiths GL, Wahren B, Hinkula J (October 2006). "Elimination of HIV-1 infection by treatment with a doxorubicin-conjugated anti-envelope antibody". AIDS. 20 (15): 1911–1915. doi: 10.1097/01.aids.0000247111.58961.60 . PMID   16988511. S2CID   42286690.
  60. ↑ Mitsuyasu R (May 2013). "Curing HIV: lessons from cancer therapy". Current Opinion in HIV and AIDS. 8 (3): 224–229. doi:10.1097/COH.0b013e32835ef0a1. PMC   3789644 . PMID   23454863.
  61. ↑ Friedman R, Caflisch A (August 2009). "Discovery of plasmepsin inhibitors by fragment-based docking and consensus scoring". ChemMedChem. 4 (8): 1317–1326. doi:10.1002/cmdc.200900078. PMID   19472268. S2CID   14642593. Archived from the original on 5 January 2013. Retrieved 28 May 2010.
  62. ↑ Gamo FJ, Sanz LM, Vidal J, de Cozar C, Alvarez E, Lavandera JL, et al. (May 2010). "Thousands of chemical starting points for antimalarial lead identification". Nature. 465 (7296): 305–310. Bibcode:2010Natur.465..305G. doi:10.1038/nature09107. PMID   20485427. S2CID   1143258.
  63. ↑ Karukstis KK, Thompson EH, Whiles JA, Rosenfeld RJ (July 1998). "Deciphering the fluorescence signature of daunomycin and doxorubicin". Biophysical Chemistry. 73 (3): 249–263. doi:10.1016/s0301-4622(98)00150-1. PMID   9700924.
  64. ↑ Mohan P, Rapoport N (December 2010). "Doxorubicin as a molecular nanotheranostic agent: effect of doxorubicin encapsulation in micelles or nanoemulsions on the ultrasound-mediated intracellular delivery and nuclear trafficking". Molecular Pharmaceutics. 7 (6): 1959–1973. doi:10.1021/mp100269f. PMC   2997862 . PMID   20957997.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.